down arrow

Perspective Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US46489V1044
USD
2.39
0.18 (8.14%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.172.41

52 Week

1.605.39
Valuation
Technical
Day's Volume

CASH

1.93 M

Shareholding (Mar 2025)

FII

6.37%

Held by 54 FIIs

DII

60.25%

Held by 34 DIIs

Promoter

5.60%

How big is Perspective Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Perspective Therapeutics, Inc. has a market capitalization of 262.03 million, with net sales of 1.47 million and a net profit of -84.69 million over the last four quarters. Shareholder's funds are 290.67 million, and total assets are 350.11 million as of Dec'24.

Market Cap: As of Jun 18, Perspective Therapeutics, Inc. has a market capitalization of 262.03 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 1.47 million and a net profit of -84.69 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 290.67 million, while total assets were reported at 350.11 million.

Read More

What does Perspective Therapeutics, Inc. do?

22-Jun-2025

Perspective Therapeutics, Inc. is a medical technology company specializing in isotope-based products for cancer treatment. As of March 2025, it reported net sales of $0 million and a net loss of $18 million, with a market cap of $262.03 million.

Overview:<BR>Perspective Therapeutics, Inc. is a medical technology company in the Pharmaceuticals & Biotechnology industry, focused on developing, manufacturing, and selling isotope-based medical products for cancer treatment.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 262.03 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.73 <BR>Return on Equity: -21.30% <BR>Price to Book: 0.92<BR><BR>Contact Details:<BR>Address: 350 Hills St Ste 106, RICHLAND WA: 99354-5511 <BR>Tel: 1 509 3751202 <BR>Website: https://isoray.com/

Read More

Who are in the management team of Perspective Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Perspective Therapeutics, Inc. includes Mr. Michael McCormick (Independent Chairman), Ms. Lori Woods (CEO and Director), Mr. Alan Hoffmann (Independent Director), and Dr. Philip Vitale (Independent Director).

As of March 2022, the management team of Perspective Therapeutics, Inc. includes Mr. Michael McCormick as the Independent Chairman of the Board, Ms. Lori Woods as the Chief Executive Officer and Director, Mr. Alan Hoffmann as an Independent Director, and Dr. Philip Vitale also serving as an Independent Director.

Read More

Is Perspective Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 22, 2025, Perspective Therapeutics, Inc. shows a mildly bullish trend with mixed signals from various indicators, including a bearish monthly MACD and underperformance against the S&P 500, resulting in a significant 1-year return of -75.36%.

As of 22 August 2025, the technical trend for Perspective Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Moving averages are mildly bullish on the daily timeframe. However, the Bollinger Bands and KST are bearish on both weekly and monthly charts, and the Dow Theory presents a mixed view with a mildly bearish weekly and mildly bullish monthly stance. <BR><BR>In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a significant 1-year return of -75.36% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish signals in other indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 255 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.71

stock-summary
Return on Equity

-26.85%

stock-summary
Price to Book

0.96

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-22 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-32.49%
0%
-32.49%
6 Months
-23.64%
0%
-23.64%
1 Year
-35.58%
0%
-35.58%
2 Years
-12.33%
0%
-12.33%
3 Years
-38.02%
0%
-38.02%
4 Years
-43.1%
0%
-43.1%
5 Years
-45.87%
0%
-45.87%

Perspective Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Perspective Therapeutics, Inc. technically bullish or bearish?

As of 22 August 2025, the technical trend for Perspective Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Moving averages are mildly bullish on the daily timeframe. However, the Bollinger Bands and KST are bearish on both weekly and monthly charts, and the Dow Theory presents a mixed view with a mildly bearish weekly and mildly bullish monthly stance. In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a significant 1-year return of -75.36% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish signals in other indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-31.24%
EBIT Growth (5y)
-274.73%
EBIT to Interest (avg)
-26.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.05
Tax Ratio
2.42%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.89%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.87
EV to EBIT
-0.49
EV to EBITDA
-0.51
EV to Capital Employed
0.49
EV to Sales
25.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-100.05%
ROE (Latest)
-21.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 32 Schemes (27.78%)

Foreign Institutions

Held by 54 Foreign Institutions (6.37%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 50.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -20.88% vs 54.61% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-21.10",
          "chgp": "-10.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.00",
          "val2": "-18.20",
          "chgp": "-20.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-82,893.10%",
          "val2": "-63,836.30%",
          "chgp": "-1,905.68%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.50",
          "val2": "1.40",
          "chgp": "7.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-64.50",
          "val2": "-39.90",
          "chgp": "-61.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-78.30",
          "val2": "-37.50",
          "chgp": "-108.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-45,940.20%",
          "val2": "-28,550.20%",
          "chgp": "-1,739.00%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.30
0.30
Operating Profit (PBDIT) excl Other Income
-23.30
-21.10
-10.43%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
-22.00
-18.20
-20.88%
Operating Profit Margin (Excl OI)
-82,893.10%
-63,836.30%
-1,905.68%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 50.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -20.88% vs 54.61% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1.50
1.40
7.14%
Operating Profit (PBDIT) excl Other Income
-64.50
-39.90
-61.65%
Interest
0.00
0.10
-100.00%
Exceptional Items
-24.10
0.00
Consolidate Net Profit
-78.30
-37.50
-108.80%
Operating Profit Margin (Excl OI)
-45,940.20%
-28,550.20%
-1,739.00%
USD in Million.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Resultsstock-summary
stock-summaryCompany CV
About Perspective Therapeutics, Inc. stock-summary
stock-summary
Perspective Therapeutics, Inc.
Pharmaceuticals & Biotechnology
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.
Company Coordinates stock-summary
Company Details
350 Hills St Ste 106 , RICHLAND WA : 99354-5511
stock-summary
Tel: 1 509 3751202
stock-summary
https://isoray.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."